Sleep Disordered Breathing and Alzheimer's Disease Biomarkers in Normal Aging and Mild Cognitive Impairment
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Sleep Disorder
- Sponsor
- NYU Langone Health
- Enrollment
- 28
- Locations
- 1
- Primary Endpoint
- Decreased cerebral blood flow (CBF)
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
The purpose of this study is to determine the sleep patterns of subjects with or without sleep disturbances (insomnia, sleep apnea) and compare these findings with their previous FDG/PIB PET, structural MRI and brain blood flow scams performed during their participation in the Following studies 'Alzheimer's Disease Core Center (ADCC) Clinical Evaluation' (IRB: 2942), MRI Progression Markers of Cognitive Decline in the Elderly' (IRB:09-0586), or 'Imaging Neuro inflammation in Alzheimer's Disease with [11C] Arachidonic Acid (AA) and PET'(IRB: 10-00442).
Investigators
Eligibility Criteria
Inclusion Criteria
- •All subjects will have participated in prior CBH studies and have agreed to an FDG, PIB and MRI scans.
Exclusion Criteria
- •Diagnosis of sleep apnea and under treatment with a continuous positive airway pressure (CPAP) machine.
- •Active depressive episode during the evaluation with a Geriatric Depression Scale score \>7 and/or a Clinical Global Impression scale for depression score \>
- •Moderate Cognitive decline (GDS \>3).
- •Severe primary or secondary insomnia except insomnia due to SDB.
Outcomes
Primary Outcomes
Decreased cerebral blood flow (CBF)
Time Frame: 1 Week
Measured by perfusion MRI
Measure of vasoreactivity to CO2 (VRCO2)
Time Frame: 1 Week
subjects will breath through a respiratory tube and CO2 will be meaured
Increase in cortical AB plaque burden
Time Frame: 1 Week
Measured by PIB PET